Max W. Carbon, Professor Emeritus of Nuclear Engineering at the University of Wisconsin, Madison, was cited by the NAE for “establishing engineering educational programs for nuclear reactor design and safety.” He chaired the Nuclear Engineering and Engineering Physics Department and its predecessor programs from 1958 to 1992. After obtaining his PhD in 1949, he went to Hanford Works, where he was responsible for the safety of the graphite piles used to produce plutonium, and subsequently engaged in the design of ICBM nose cones. He is a Fellow of the American Nuclear Society; served on the Federal Advisory Committee on Reactor Safeguards, on the University of Chicago [UC] Special Advisory Committee for the Integral Fast Reactor [chair], on the National Nuclear Accrediting Board for the Institute for Nuclear Power Operations [INPO], on the Nuclear Safety Review and Audit Committee for the Kewaunee Nuclear Power plant, and on the UC Special Advisory Committee for the Nuclear Technology Program at Argonne National Laboratory [chair].
 

Richard W. Korsmeyer is currently global head of licensing for Worldwide Pharmaceutical Sciences, and senior research fellow with Pfizer. He has been a major figure in the development and commercialization of drug delivery systems. Specifically, he is the co-inventor of a method that permits delivery of a full course of the antibiotic azithromycin therapy with a single oral dose, which was developed into the commercial product, Zmax™. He has authored 65 publications and 25 patents. He is a member of the Connecticut Nanotech Coordinating Group, member of several journal editorial boards and a Fellow of the American Institute of Medical and Biological Engineering (AIMBE). The NAE cited Korsmeyer’s “contributions to drug delivery formulations and medical devices.”
 

Antonios G. Mikos is the Louis Calder Professor of Bioengineering and Professor of Chemical and Biomolecular Engineering and the director of the Center for Excellence in Tissue Engineering at Rice University. His research focuses on the synthesis, processing, and evaluation of new biomaterials for use as scaffolds for tissue engineering, as carriers for controlled drug delivery, and as non-viral vectors for gene therapy. His work has led to the development of novel orthopedic, dental, cardiovascular, neurologic, and ophthalmologic biomaterials. An author of over 420 publications and 25 patents, he has been cited more than 28,000 times. His citation from the NAE reads: “For advances in tissue engineering, regenerative medicine, biomaterials, and drug delivery, including development of biodegradable polymers.”